Literature DB >> 33131335

An overview of disease models for NLRP3 inflammasome over-activation.

Hongliang Zhang1, Ayesha Zahid2, Hazrat Ismail3, Yujie Tang1, Tengchuan Jin1,2,4, Jinhui Tao1.   

Abstract

Introduction: Inflammatory reactions, including those mediated by the NLRP3 inflammasome, maintain the body's homeostasis by removing pathogens, repairing damaged tissues, and adapting to stressed environments. However, uncontrolled activation of the NLRP3 inflammasome tends to cause various diseases using different mechanisms. Recently, many inhibitors of the NLRP3 inflammasome have been reported and many are being developed. In order to assess their efficacy, specificity, and mechanism of action, the screening process of inhibitors requires various types of cell and animal models of NLRP3-associated diseases.Areas covered: In the following review, the authors give an overview of the cell and animal models that have been used during the research and development of various inhibitors of the NLRP3 inflammasome.Expert opinion: There are many NLRP3 inflammasome inhibitors, but most of the inhibitors have poor specificity and often influence other inflammatory pathways. The potential risk for cross-reaction is high; therefore, the development of highly specific inhibitors is essential. The selection of appropriate cell and animal models, and combined use of different models for the evaluation of these inhibitors can help to clarify the target specificity and therapeutic effects, which is beneficial for the development and application of drugs targeting the NLRP3 inflammasome.

Entities:  

Keywords:  NLRP3 inflammasome; disease models; drug discovery; inflammatory diseases; inhibitor screening

Year:  2020        PMID: 33131335     DOI: 10.1080/17460441.2021.1844179

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  6 in total

Review 1.  Strategies of Targeting Inflammasome in the Treatment of Systemic Lupus Erythematosus.

Authors:  Yaling Liu; Xinyu Tao; Jinhui Tao
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

Review 2.  Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases.

Authors:  Christine Péladeau; Jagdeep K Sandhu
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

3.  Therapeutic Modulation of NLRP3 for Treatment of Cancer, Alzheimer's Disease, and Trauma.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-06-23       Impact factor: 4.632

4.  Short-Chain Fatty Acids Reduce Oligodendrocyte Precursor Cells Loss by Inhibiting the Activation of Astrocytes via the SGK1/IL-6 Signalling Pathway.

Authors:  Yanmin Gao; Di Xie; Yang Wang; Lei Niu; Hua Jiang
Journal:  Neurochem Res       Date:  2022-09-13       Impact factor: 4.414

5.  IIIM-941, a Stilbene Derivative Inhibits NLRP3 Inflammasome Activation by Inducing Autophagy.

Authors:  Mehboob Ali; Mehak Gupta; Abubakar Wani; Ankita Sharma; Mohd Abdullaha; Dilpreet Kour; Sushil Choudhary; Sandip B Bharate; Gurdarshan Singh; Ajay Kumar
Journal:  Front Pharmacol       Date:  2021-06-25       Impact factor: 5.810

Review 6.  Sex-Related Overactivation of NLRP3 Inflammasome Increases Lethality of the Male COVID-19 Patients.

Authors:  Hongliang Zhang; Yujie Tang; Jinhui Tao
Journal:  Front Mol Biosci       Date:  2021-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.